https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35727 Wed 14 Jun 2023 12:38:16 AEST ]]> Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6849 Wed 11 Apr 2018 16:39:01 AEST ]]> Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45582 p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). Conclusion: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.]]> Wed 02 Nov 2022 10:37:04 AEDT ]]> The effectiveness of online interventions for patients with gynecological cancer: an integrative review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37041 Thu 24 Mar 2022 11:31:27 AEDT ]]> Improving knowledge, attitudes, and uptake of cervical cancer prevention among female students: A systematic review and meta-analysis of school-based health education https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47322 Thu 02 May 2024 14:42:59 AEST ]]> Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21178 BRCA1, EN1, DLEC1, HOXA9, RASSF1A, GATA4, GATA5, HSULF1, CDH1, SFN) were examined and compared in a cohort of 80 primary HGSOC and 12 benign ovarian surface epithelium (OSE) samples using methylation-specific headloop suppression PCR. Results: The genes were variably methylated in primary HGSOC, with HOXA9 methylation observed in 95% of cases. Most genes were rarely methylated in benign OSE, with the exception of SFN which was methylated in all HGSOC and benign OSE samples examined. Methylation of DLEC1 was associated with disease recurrence, independent of tumor stage and suboptimal surgical debulking (HR 3.5 (95% CI:1.10–11.07), p = 0.033). A combination of the methylation status of HOXA9 and EN1 could discriminate HGSOC from benign OSE with a sensitivity of 98.8% and a specificity of 91.7%, which increased to 100% sensitivity with no loss of specificity when pre-operative CA125 levels were also incorporated. Conclusions: This study provides further evidence to support the feasibility of detecting altered DNA methylation patterns as a potential diagnostic and prognostic approach for HGSOC.]]> Sat 24 Mar 2018 07:58:05 AEDT ]]> Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: results from the LACE trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27255 Sat 24 Mar 2018 07:29:12 AEDT ]]> Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: a systematic review and network meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46176 Mon 14 Nov 2022 08:57:36 AEDT ]]> Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32152 Mon 07 May 2018 14:16:23 AEST ]]> The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32153 Mon 07 May 2018 14:14:20 AEST ]]> Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47888 Mon 06 Feb 2023 12:00:58 AEDT ]]> The preventable burden of endometrial and ovarian cancers in Australia: a pooled cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35870 Fri 21 Oct 2022 11:25:56 AEDT ]]> PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45708 Fri 04 Nov 2022 10:18:27 AEDT ]]>